保诺-桑迪亚任命新首席财务官和高级运营副总裁

新任核心领导助益布局公司下一阶段发展

Key new hires position company for next stage of growth

SAN DIEGO and SHANGHAI, June 30, 2021 – BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today the appointment of two senior leadership positions: Nee Chuan Teo as Chief Financial Officer and Alice Lv, PhD as Senior Vice President of Operations. Both directly report to the global CEO.（圣地亚哥，上海，2021 年 6 月 30 日）—— 保诺-桑迪亚是一家由安宏资本领投，业内领先的药物研发服务机构。公司今日宣布，任命赵汝泉先生担任首席财务官，吕红博士担任高级运营副总裁。两位新领导都直接汇报给全球首席执行官。

“The appointment of Teo and Alice adds leadership and experience that will support the next phase of our growth,” said Haijun Dong, PhD, Global CEO of BioDuro-Sundia. “We are now one of the largest CRDMOs in the world with major China and US operations. Our next growth stage requires intense financial procedures, policies, and controls as we access new capital markets, and equally strong operational processes as we scale into much larger new facilities.”

保诺-桑迪亚全球首席执行官 (CEO) 董海军博士表示：“保诺-桑迪亚是一家全球领先的合同研究、工艺开发和生产公司（CRDMO），拥有全球10大分支机构，2,000多名员工，主要在中国和美国开展业务。公司在下一阶段，将会不断扩展规模、建立新的研发和生产基地。Teo和Alice的到任，将为公司建立更严格的财务程序、方针和管控制度，带来更强有力的企业运营支撑。新的领导团队将全力支持公司的下一轮布局和快速发展。”

Teo Nee Chuan, Chief Financial Officer

首席财务官赵汝泉先生

Teo will provide financial leadership across BioDuro-Sundia’s global organization. Teo brings with him more than 20 years of professional finance experience, including international publicly-traded companies. Prior to BioDuro-Sundia, Teo served as chief financial officer for multiple companies in Greater China, including Huazhu Group, Rnomac International Limited, and DDB Greater China Group; he also served as independent director of NASDAQ-listed 111, Inc. (ticker symbol: YI). Teo has held international roles with Ernst & Young in Kuala Lumpur and Toronto, including senior management positions within their Transaction Advisory Services group.

Teo 将在保诺-桑迪亚的全球组织结构中发挥财务领导作用。Teo 拥有 20 余年的专业财务经验，曾在国际上市公司任职。在加入保诺-桑迪亚之前，Teo 曾担任大中华区多家公司的首席财务官，其中包括华住集团、瑞迈国际有限公司和 DDB 大中华集团；他还曾担任在纳斯达克上市的 111 集团（股票代码：YI）的独立董事。Teo 曾在吉隆坡和多伦多的安永会计师事务所担任国际职务，包括在其交易咨询服务部门担任高管职务。

“I am very excited to join BioDuro-Sundia at such an exciting time for the company,” said Teo. “The business has grown rapidly in recent years. I look forward to working with the leadership team and our partners at Advent International to continue that expansion, providing the financial oversight that is needed to support our growth.”

“我很高兴能在如此振奋人心的时刻加入保诺-桑迪亚。保诺-桑迪亚近年来增长迅速，我期待与我们的领导团队，以及合作伙伴安宏等一起紧密工作，继续扩展业务，同时做好财务监督，全力支持公司在下一阶段的发展和布局。” Teo说道。

BioDuro-Sundia’s outgoing CFO, Jeff Blazevich, joined the company in 2019, and provided critical financial leadership supporting the 2020 merger of BioDuro and Sundia, as well as the initial buildout of the company’s 300,000ft2 R&D facility in Wuxi City. Blazevich will continue to serve as advisor to BioDuro-Sundia’s leadership team, exploring additional growth opportunities.

保诺-桑迪亚即将离任的 CFO Jeff Blazevich 于 2019 年加入公司，任职期间发挥了重要的财务领导作用，为 2020 年保诺和桑迪亚的合并、公司在江苏省无锡市的 300,000 平方英尺研发基地的早期建设提供了支持。Blazevich 将继续担任保诺-桑迪亚领导团队的顾问，支持公司探寻更多发展机遇。

“On behalf of our shareholders and the Board, we welcome Teo and Alice, who we believe are the best additions to the existing leadership team led by Dr. Dong. We also wish a tremendous thank you to Jeff,” said David Preston, Chairman of the Board of BioDuro-Sundia.

“我们代表股东和董事会欢迎 Teo 和 Alice的到任，他们的加入，是对由董博士带领的现有领导团队力量的最好补充。我们也衷心感谢 Jeff。” 保诺-桑迪亚董事长 David Preston 表示。

Dr. Alice Lv, Senior Vice President, Operations

高级运营副总裁吕红博士

Alice will be responsible for overseeing all operations and functions that support the research of more than 2,000 employees around the world. Alice brings more than 24 years of professional experience in both pharmaceutical R&D and CRO sectors. Prior to joining BioDuro-Sundia, Alice was Business Advisor of Lilly Research Laboratories in Indianapolis, COO of the Lilly China R&D Center in Shanghai, and held senior positions in project management and operations for international organizations and China-based CROs; in those positions, she built a solid track record in operations, information security, IT, compliance and project management.

吕红博士将领导公司的所有运营事务，全力支持全球10大办事处，2,000多名员工的研发和生产业务。吕红博士在医药研发和合同研究机构 (CRO) 领域拥有超过 24 年的专业经验。在加入保诺-桑迪亚之前，吕红博士曾担任位于美国印第安纳波利斯市的礼来研究实验室的业务顾问、礼来中国上海研发中心的首席运营官 (COO)，并在国际组织和中国的 CRO 公司担任过高级项目管理和运营职务。担任这些职务期间，她在运营、信息安全、IT、合规和项目管理方面业绩斐然。

“I am excited to join BioDuro-Sundia at this critical time in the company’s growth,” said Lv. “Following the merger of BioDuro and Sundia, and the buildout of two new facilities in Wuxi and Bengbu, the company is now at a point of scale, where operational efficiencies become critically important—more than ever—to the success of the company and the success of our clients.”

吕红博士说：“我很高兴能在公司发展的关键时刻加入保诺-桑迪亚。随着保诺和桑迪亚的合并、无锡和蚌埠两个新基地的扩建，公司的发展已经到了一定的规模。为了更好地实现公司和客户的双赢，专业化运营和效率的提升尤为重要。”

About BioDuro-Sundia

关于保诺-桑迪亚

BioDuro-Sundia, an Advent International portfolio company, is a leading contract research, development and manufacturing organization (CRDMO) that provides biopharmaceutical partners with fully integrated services to support drug discovery, development and manufacturing for both drug substance and drug product. The company is the industry’s third largest, with major operations in China and the US—featuring more than 2,000 employees and10 global sites.

保诺-桑迪亚，安宏资本旗下投资企业之一，是业内领先的合同研究、工艺开发和生产公司 (CRDMO)，专业为生物制药客户提供全面整合服务，支持药物发现、开发和生产（包括原料药和成品药）。作为全球第三大 CRDMO 公司，保诺-桑迪亚的 10 大办事处遍布全球，旗下拥有 2000 多名员工，在中国和美国开展主要业务。

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The company has research sites, as well as GMP manufacturing facilities in both China and the US. The one-stop-shop operation helps biopharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes.

保诺-桑迪亚在大小分子发现、开发和放大方面拥有核心专业知识，支持 IND 申报，拥有独特的专利技术平台（例如不溶性化合物生物利用度增强平台）。公司在中国和美国均设有研发中心和生产基地。保诺-桑迪亚采用“一站式”运营模式，有效帮助生物制药客户加快发现进程并降低开发风险，从而创造更高价值的药物。

BioDuro-Sundia investment is led by Advent International, with backing from Bridgewest Business Group.

保诺-桑迪亚由安宏资本领投，Bridgewest Business Group 为共同投资者。

For more information, visit:

www.bioduro-sundia.com

更多详情，请访问：

www.bioduro-sundia.com

About Advent International

关于安宏资本

Founded in 1984, Advent International is one of the largest and most experienced global private equity investors. The firm has invested in over 350 private equity transactions in 41 countries, and as of June 30, 2020, had $58.4 billion in assets under management. With 15 offices in 12 countries, Advent has established a globally integrated team of over 200 investment professionals across North America, Europe, Latin America and Asia. The firm focuses on investments in five core sectors, including business and financial services; health care; industrial; retail, consumer and leisure; and technology. After 35 years dedicated to international investing, Advent remains committed to partnering with management teams to deliver sustained revenue and earnings growth for its portfolio companies.

安宏资本成立于 1984 年，是全球规模最大且最富经验的私募股权投资基金之一。自成立以来，安宏资本在 41 个国家完成了超过350项私募股权交易。截至 2020 年 6 月 30 日，公司资产管理规模达 584 亿美元。公司在全球四大洲 12 个国家设立了 15 个办公室，并拥有一支超过 200 名专业投资人士的国际团队，业务遍布北美、欧洲、拉丁美洲和亚洲。公司专注于五个核心投资领域－商业和金融服务业，医疗健康，工业，零售、消费品与休闲，以及科技、媒体和电信业。35 年以来，安宏资本致力于国际投资市场，始终与管理团队保持协作，推动被投公司现收入和利润的可持续增长。

For more information, visit:

www.adventinternational.com

更多详情，请访问：

www.adventinternational.com

About Bridgewest Business Group

关于 Bridgewest Business Group

Founded in 1999, The Bridgewest Business Group is a closely held investment company that seeks to create long term value through application of superior industry knowledge, operational expertise and significant financial resources to attractive investment opportunities. The Group structures its global investments across four functional areas including private equity, real estate, capital markets and financial services. The Group’s private equity investments are primarily in biotech, wireless communications, infrastructure for IoT, and semiconductor. Bridgewest is based in San Diego, CA and has investments across the USA, Europe, Asia and Australasia.

Bridgewest Business Group 成立于 1999 年，是一家封闭型投资公司，旨在通过应用卓越的行业经验、专业的运营知识和大量的金融资源，创造长期价值，从而吸引投资机会。集团的全球投资覆盖四个职能领域，包括私募股权、房地产、资本市场和金融服务。私募股权投资主要集中在生物技术、无线通信、物联网基础设施和半导体领域。Bridgewest 总部位于加利福尼亚州圣迭戈，投资业务遍布美国、欧洲、亚洲和大洋洲。

For more information, visit:

www.bridgewestgroup.com

更多详情，请访问：

www.bridgewestgroup.com